A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
Weiming Fan,Chuan Wang,Xuefeng Zhong,Yating Zheng,Tingting Chen,Mengli Huang,Shuying Su
DOI: https://doi.org/10.2147/OTT.S390458
IF: 4
2023-01-19
OncoTargets and Therapy
Abstract:Weiming Fan, 1, &ast Chuan Wang, 1, &ast Xuefeng Zhong, 2 Yating Zheng, 2 Tingting Chen, 2 Mengli Huang, 2 Shuying Su 1 1 Department of Biliary-Pancreatic Surgery, First People's Hospital of Foshan, Foshan, People's Republic of China; 2 The Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shuying Su, Department of Biliary-Pancreatic Surgery, First People's Hospital of Foshan, No. 81 North Lingnan Avenue, Chancheng District, Foshan, Guangdong Province, People's Republic of China, Email Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive and malignant subtype of biliary duct tumors. The poor prognosis of advanced ICC brings great challenges to clinical treatment, and chemotherapy-based therapy remains the standard first-line regimen. In recent years, the development of clinical research on targeted therapy for biliary duct tumors has brought new strategies for clinical treatment, but the targets are limited. Herein, we reported a 68-year-old patient with metastasis ICC harboring CDKN2A/B loss, who achieved a partial response (PR) after the first-line treatment with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor called palbociclib, and no obvious side effects were observed. As of the latest follow-up time, the progression-free survival (PFS) had lasted for 20 months. This case reveals the molecular characteristic of ICC patients who respond to palbociclib treatment and illustrates the importance of performing a multiple-gene panel test in ICC patients. Keywords: intrahepatic cholangiocarcinoma, ICC, CDKN2A/B loss, palbociclib, CDK4/6 inhibitor, next-generation sequencing, NGS Intrahepatic cholangiocarcinoma (ICC) is a subtype of cholangiocarcinoma often characterized by acinar or small tubular adenocarcinoma, and its incidence continues to increase in both eastern and western countries. 1,2 ICC has a poor prognosis due to its high degree of malignancy, susceptibility to recurrence and metastasis. 2 It is well known that radical surgical resection is the best choice for ICC patients to obtain a long-term survival outcome, especially those in the early stages. However, even with radical resection, ICC is still highly susceptible to postoperative recurrence and metastasis, with a postoperative recurrence rate of 40–80%. 2 In addition, most ICC patients were already in the middle and late stages at the time of initial diagnosis, and lost the opportunity of radical surgery, which made diagnosis and treatment more difficult. 1 As for patients with unresectable or metastatic ICC, the gemcitabine and cisplatin regimen (GemCis) remains the standard systemic treatment. 1 Although the response rate of GemCis is about 80%, the median overall survival (OS) is only 11.7 months and the median progression-free survival (PFS) is only 8.0 months, and not all patients can tolerate the side effect of chemotherapy, 3 so a number of patients who can benefit from chemotherapy are limited. Targeted therapies for cholangiocarcinoma have made encouraging progress in recent years, in particular drugs targeting FGFR2 fusions or rearrangements (pemigatinib, infigratinib, etc) and IDH1 mutations (ivosidenib), which have been approved by the FDA as a subsequent-line therapy option for patients with cholangiocarcinoma. 4,5 The frequency of FGFR2 and IDH1 alterations in ICC patients is much higher than that of other cholangiocarcinoma subtypes, 4 suggesting that targeted therapy has a better clinical application prospect in ICC. Even so, the proportion of ICC patients with FGFR2 fusion or rearrangement and IDH1 mutation is only 11–45% 1 and 10–20%, 5 respectively, indicating that a significant proportion of patients would not benefit from either type of targeted therapy described above. Therefore, it is necessary to explore other biomarkers that can guide the targeted therapy of ICC patients in order to promote the development of patient-specific therapy. Herein, we report an ICC patient with CDKN2A/B loss, who underwent postoperative metastasis, achieved a partial response (PR) after first-line treatment with palbociclib (cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor), and the PFS had lasted for 20 months. A 68-year-old man was admitted to the hospital on May 28, 2020, due to the discovery of a liver mass. He had a history of gout and hypertension, but no history of viral hepatitis, chronic disease, hereditary disease, or surgery. Laboratory examinations of the patient before therapy revealed alpha-fetoprotein ( -Abstract Truncated-
oncology,biotechnology & applied microbiology